Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Treasury Shares (2018 - 2026)

Aytu Biopharma has reported Treasury Shares over the past 8 years, most recently at $4.0 for Q4 2025.

  • Quarterly Treasury Shares fell 99.29% to $4.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 through Dec 2025, down 99.29% year-over-year, with the annual reading at $24105.0 for FY2024, 36.69% down from the prior year.
  • Treasury Shares was $4.0 for Q4 2025 at Aytu Biopharma, down from $31294.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $2.2 million in Q4 2021 and troughed at $4.0 in Q1 2025.
  • The 5-year median for Treasury Shares is $37929.0 (2023), against an average of $459971.6.
  • Year-over-year, Treasury Shares tumbled 99.95% in 2021 and then surged 119579.79% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $2.2 million in 2021, then plummeted by 99.62% to $8167.0 in 2022, then skyrocketed by 364.42% to $37929.0 in 2023, then tumbled by 98.51% to $565.0 in 2024, then crashed by 99.29% to $4.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Treasury Shares are $4.0 (Q4 2025), $31294.0 (Q3 2025), and $4.0 (Q1 2025).